Arrowhead Pharmaceuticals (ARWR) return on equity (ROE)

Return on equity · fiscal 2026
-1439.4%

Arrowhead Pharmaceuticals (ARWR) earned a return on equity of -1439.4% in fiscal 2026 (the year ended September 30, 2026). That is 1439.1 percentage points lower than the -0.3% of fiscal 2025. Figures as of 17 Nov 2026, 21:34 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2026
-1439.4%
Change on fiscal 2025
−1439.1 pts
Highest on record
27.8%fiscal 2019
Lowest on record
-1439.4%fiscal 2026
Fiscal years on record
242003–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Arrowhead Pharmaceuticals return on equity (ROE), in more detail

Across the 24 fiscal years on record (2003–2026), the highest was 27.8% in fiscal 2019 and the lowest -1439.4% in fiscal 2026. The fiscal 2026 figure is no higher than in any of the 23 earlier fiscal years on record, whose median is -56.8%.

History · 24 fiscal years

Return on equity by fiscal year

Arrowhead Pharmaceuticals return on equity (ROE), year by year

Arrowhead Pharmaceuticals (ARWR) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2026-1439.4% 1439.1 pts down
2025-0.3% 322.9 pts up
2024-323.3% 247.6 pts down
2023-75.7% 31.5 pts down
2022-44.2% 9.7 pts down
2021-34.5% 16.1 pts down
2020-18.3% 46.1 pts down
201927.8% 84.6 pts up
2018-56.8% 14.6 pts down
2017-42.2% 43.3 pts up
2016-85.5% 2.1 pts down
2015-83.4% 48.2 pts down
2014-35.2% 78.0 pts up
2013-113.3% 97.7 pts up
2012-211.0% 186.5 pts down
2011-24.5% 39.4 pts up
2010-63.8% 333.6 pts up
2009-397.5% 176.0 pts down
2008-221.4% 105.3 pts down
2007-116.1% 52.9 pts down
2006-63.2% 39.1 pts down
2005-24.0% 17.3 pts down
2004-6.7% 0.0 pts
2003-6.7%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Arrowhead Pharmaceuticals and comparable companies
CompanyReturn on equityFiscal year
Axsome Therapeutics AXSM-207.5%2025
Chemed CHE27.1%2025
Oruka Therapeutics ORKA-22.3%2025
Arrowhead Pharmaceuticals ARWR-1439.4%2026
MSA Safety MSA20.4%2025
CG Oncology CGON-21.4%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on ARWR

Arrowhead Pharmaceuticals, figure by figure

Arrowhead Pharmaceuticals (ARWR) overview: price, valuation and scorecardAll health care companies by market value

Arrowhead Pharmaceuticals return on equity (ROE): questions and answers

What is Arrowhead Pharmaceuticals's return on equity?

Arrowhead Pharmaceuticals (ARWR) earned a return on equity of -1439.4% in fiscal 2026 (the year ended September 30, 2026). That is 1439.1 percentage points lower than the -0.3% of fiscal 2025.

Is Arrowhead Pharmaceuticals's return on equity high or low compared with its own history?

The fiscal 2026 figure is no higher than in any of the 23 earlier fiscal years on record, whose median is -56.8%.

What are the highest and lowest return on equity figures on record for Arrowhead Pharmaceuticals?

Across the 24 fiscal years on record (2003–2026), the highest was 27.8% in fiscal 2019 and the lowest -1439.4% in fiscal 2026.

How is Arrowhead Pharmaceuticals's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Arrowhead Pharmaceuticals (ARWR) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/ARWR/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.